Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous disease in which management requires integration of clinical assessment, cardiovascular physiology, multimodality imaging, functional evaluation, and arrhythmic risk. This review examines contemporary evaluation, risk stratification, an...
A. Parodi, B. Baù, G. Piccolboni et al.· Journal of Clinical Medicine· 0 citations
While BB and RASi are commonly used in ES-HCM, MRA and SGLT2i are prescribed less frequently and in patients with a worse clinical profile, suggesting both clinical inertia and limitations inherent to the disease pathophysiology.
G. Tini, Isabella Perlati, S. Palma et al.· International Journal of Car...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.